| Synonyms: | |
| Status: | Approved (1995) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | V03AF02 |
| UNII: | 048L81261F |
| InChI Key | BMKDZUISNHGIBY-ZETCQYMHSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C11H16N4O4 |
| Molecular Weight | 268.27 |
| AlogP | -2.71 |
| Hydrogen Bond Acceptor | 6.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 98.82 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 0.0 |
| Heavy Atoms | 19.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | DNA topoisomerase II inhibitor | EMA |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hepatoblastoma | 3 | D018197 | ClinicalTrials |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | D054198 | ClinicalTrials |
| Myelodysplastic Syndromes | 2 | D009190 | ClinicalTrials |
| Leukemia, Myeloid, Acute | 2 | D015470 | ClinicalTrials |
| Rhabdomyosarcoma | 2 | D012208 | ClinicalTrials |
| Multiple Sclerosis | 2 | D009103 | ClinicalTrials |
| Neuroblastoma | 2 | D009447 | ClinicalTrials |
| Sarcoma | 2 | D012509 | ClinicalTrials |
| Sarcoma, Ewing | 2 | D012512 | ClinicalTrials |
| Ganglioneuroblastoma | 2 | D018305 | ClinicalTrials |
| Heart Defects, Congenital | 1 | D006330 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Osteosarcoma | 1 | D012516 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 24584-09-6 |
| ChEBI | 50223 |
| ChEMBL | CHEMBL1738 |
| DrugBank | DB00380 |
| DrugCentral | 839 |
| EPA CompTox | DTXSID3040647 |
| FDA SRS | 048L81261F |
| Human Metabolome Database | HMDB0014524 |
| Guide to Pharmacology | 7330 |
| PharmGKB | PA449259 |
| PubChem | 71384 |
| SureChEMBL | SCHEMBL18400 |
| ZINC | ZINC000087515509 |